[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.106.138. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
May 2007

Methotrexate and Risk for Lymphoma

Arch Dermatol. 2007;143(5):659-675. doi:10.1001/archderm.143.5.663-b

Stern's report, “Lymphoma Risk in Psoriasis: Results of the PUVA Follow-up Study,”1 is extremely interesting and beckons us to question “Why?” and “Should we be doing anything differently for our patients being treated with methotrexate?” Stern examined the cohort of 1380 patients initially treated with psoralen–UV-A from 1975 through 1976 and found that the incidence of lymphoma was increased in the subgroup of patients who had been exposed to high levels of methotrexate (incidence rate ratio, 4.39; 95% confidence interval, 1.59-12.06).

First Page Preview View Large
First page PDF preview
First page PDF preview
×